To our knowledge, our study is the largest screening of KRAS mutations in plasma samples of pancreatic cancer cases, other pathological pancreatic conditions and healthy controls allowing for the comprehensive assessment of the sensitivity and specificity of KRAS mutations as non-invasive biomarkers for the detection of pancreatic cancer. Here, KRAS is linked to familial pancreatic carcinoma.